MedPath

Disulfiram

Generic Name
Disulfiram
Brand Names
Antabuse
Drug Type
Small Molecule
Chemical Formula
C10H20N2S4
CAS Number
97-77-8
Unique Ingredient Identifier
TR3MLJ1UAI
Background

A carbamate derivative used as an alcohol deterrent. It is a relatively nontoxic substance when administered alone, but markedly alters the intermediary metabolism of alcohol. When alcohol is ingested after administration of disulfiram, blood acetaldehyde concentrations are increased, followed by flushing, systemic vasodilation, respiratory difficulties, nausea, hypotension, and other symptoms (acetaldehyde syndrome). It acts by inhibiting aldehyde dehydrogenase.

Indication

For the treatment and management of chronic alcoholism

Associated Conditions
Chronic Alcoholism
Associated Therapies
-

Disulfiram as a Modulator of Amyloid Precursor Protein-processing

Completed
Conditions
Alcohol Addiction
First Posted Date
2017-07-11
Last Posted Date
2017-07-24
Lead Sponsor
Johannes Gutenberg University Mainz
Target Recruit Count
17
Registration Number
NCT03212599

Bioavailability of Disulfiram and Metformin in Glioblastomas

Early Phase 1
Terminated
Conditions
Glioblastoma
Interventions
First Posted Date
2017-05-12
Last Posted Date
2020-09-28
Lead Sponsor
Sahlgrenska University Hospital, Sweden
Target Recruit Count
3
Registration Number
NCT03151772
Locations
🇸🇪

Sahlgrenska University Hospital, Göteborg, Sweden

A Phase Ib Study of Intravenous Copper Loading With Oral Disulfiram in Metastatic, Castration Resistant Prostate Cancer

Phase 1
Terminated
Conditions
Prostate Cancer
Interventions
First Posted Date
2016-11-15
Last Posted Date
2021-09-16
Lead Sponsor
Daniel George, MD
Target Recruit Count
9
Registration Number
NCT02963051
Locations
🇺🇸

Duke University Medical Center, Durham, North Carolina, United States

A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma

First Posted Date
2016-05-12
Last Posted Date
2021-10-05
Lead Sponsor
University of Ulm
Target Recruit Count
10
Registration Number
NCT02770378
Locations
🇩🇪

University of Ulm School of Medicine, Ulm, Baden-Württemberg, Germany

Neural Mechanisms of Disulfiram Effects

Phase 4
Completed
Conditions
Alcohol Use Disorder
Interventions
First Posted Date
2016-04-12
Last Posted Date
2020-11-23
Lead Sponsor
New York State Psychiatric Institute
Target Recruit Count
7
Registration Number
NCT02735577
Locations
🇺🇸

NYPInstitute, New York, New York, United States

Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma

Phase 1
Active, not recruiting
Conditions
Glioblastoma Multiforme
Interventions
Drug: Disulfiram
Drug: Copper Gluconate
Procedure: Surgery
Radiation: Radiation
Drug: Temozolomide
First Posted Date
2016-03-22
Last Posted Date
2024-07-29
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
35
Registration Number
NCT02715609
Locations
🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

Disulfiram in Recurrent Glioblastoma

Phase 2
Completed
Conditions
Glioma
Glioblastoma
Interventions
Drug: Disulfiram
Dietary Supplement: Copper
Drug: Alkylating Agents
First Posted Date
2016-02-10
Last Posted Date
2021-03-18
Lead Sponsor
Sahlgrenska University Hospital, Sweden
Target Recruit Count
88
Registration Number
NCT02678975
Locations
🇸🇪

Dept. of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden

🇸🇪

Ryhov County Hospital, Jönköping, Sweden

🇸🇪

Linköping University Hospital, Linkoping, Sweden

and more 5 locations

Disulfiram and Chemotherapy in Treating Patients With Refractory Solid Tumors or Metastatic Pancreatic Cancer

Phase 1
Terminated
Conditions
Refractory Malignant Solid Neoplasm
Stage IV Pancreatic Cancer AJCC v8
Metastatic Pancreatic Adenocarcinoma
Interventions
Drug: Disulfiram
Drug: Chemotherapy
Drug: Gemcitabine Hydrochloride
Other: Laboratory Biomarker Analysis
First Posted Date
2016-02-02
Last Posted Date
2025-01-07
Lead Sponsor
Mayo Clinic
Target Recruit Count
16
Registration Number
NCT02671890
Locations
🇺🇸

Mayo Clinic in Rochester, Rochester, Minnesota, United States

🇺🇸

Sanford Thief River Falls Medical Center, Thief River Falls, Minnesota, United States

A PET Exploration of the Mechanism of Action of Dopamine Beta-hydroxylase Inhibition in Cocaine Addicts

Phase 4
Withdrawn
Conditions
Cocaine Dependence
Interventions
Drug: Disulfiram
Drug: Placebo
First Posted Date
2014-05-08
Last Posted Date
2014-12-09
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Registration Number
NCT02134002
Locations
🇫🇷

Paul Brousse Hospital, Villejuif, France

Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study

Phase 1
Completed
Conditions
Human Immunodeficiency Virus
HIV
Interventions
First Posted Date
2013-09-17
Last Posted Date
2020-05-05
Lead Sponsor
University of California, San Francisco
Target Recruit Count
30
Registration Number
NCT01944371
Locations
🇦🇺

Alfred Hospital, Melbourne, Australia

🇺🇸

San Francisco General Hospital, San Francisco, California, United States

© Copyright 2025. All Rights Reserved by MedPath